Details and outcomes of a large cohort of MOG-IgG associated optic neuritis

John Chen, Eoin P. Flanagan, M. Tariq Bhatti, Nanthaya Tisavipat, Sepideh Jamali, Amy Kunchok, Eric R. Eggenberger, Marie Di Nome, Elias S. Sotirchos, Eleni S. Vasileiou, Amanda D. Henderson, Anthony C. Arnold, Laura Bonelli, Nicolas Seleme, Alvaro J. Mejia-Vergara, Heather E. Moss, Tanyatuth Padungkiatsagul, Hadas Stiebel-Kalish, Itay Lotan, Adi Wilf-YarkoniMark A. Hellmann, Amrita Vuppala, David Hodge, Sean J. Pittock

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The goal of this study was to examine the temporal relationship of eye pain to visual loss and investigate whether timing of steroid treatment affects the rate and extent of visual recovery in optic neuritis (ON) from MOG-IgG associated disease (MOGAD) in a large cohort of MOGAD patients with ON. Methods: This is a multicenter, retrospective cohort study of consecutive MOGAD patients with ON attacks seen from 2017 to 2021 fulfilling the following criteria: (1) clinical history of ON; (2) MOG-IgG seropositivity. ON attacks were evaluated for presence/duration of eye pain, nadir of vision loss, time to intravenous methylprednisolone (IVMP) treatment, time to recovery, and final visual outcomes. Results: There were 107 patients with 140 attacks treated with IVMP and details on timing of treatment and outcomes. Eye pain was present in 125/140 (89%) attacks with pain onset a median of 3 days (range, 0 to 20) prior to vision loss. Among 46 ON attacks treated with IVMP within 2 days of onset of vision loss, median time to recovery was 4 days (range, 0 to 103) compared to 15 days (range, 0 to 365) in 94 ON attacks treated after 2 days (p = 0.004). Those treated within 2 days had less severe VA loss at time of treatment (median LogMAR VA 0.48, range, 0.1 to 3) compared to those treated after 2 days (median LogMAR VA 1.7, range, 0 to 3; p < 0.001), and were more likely to have a VA outcome of 20/40 or better (98% vs 83%, p = 0.01). After adjustment for the initial VA at time of treatment, the differences in final VA were no longer significantly different (p = 0.14). In addition, some patients were documented to recover without steroid treatment. Conclusion: This study suggests that pain precedes vision loss in the majority of ON attacks and early steroids may lead to better outcomes in MOG-IgG ON, but some patients can recover without steroid treatment. Prospective randomized clinical trials are required to confirm these findings.

Original languageEnglish (US)
Article number104237
JournalMultiple Sclerosis and Related Disorders
Volume68
DOIs
StatePublished - Dec 2022

Keywords

  • MOG-IgG associated disease
  • MOGAD
  • Optic neuritis
  • Pain
  • Steroids

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Details and outcomes of a large cohort of MOG-IgG associated optic neuritis'. Together they form a unique fingerprint.

Cite this